Faslodex Spermiogenesis Inhibitor
Antiestrogen ICI 182780, Fulvestrant
- User: Male
- Hormonal: Hormonal
-
Delivery type:
- Injectable
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): University of Illinois
Details
- API: ICI 182,780
- Target: Estrogen Receptor Alpha
-
Mechanism of Action:
- Reduced Sperm Production
- Inactive Materials: Undetermined
- Regimen: Undetermined
- MPT: Not Potential MPT
Product Status
No additional published research on the antiestrogen ICI 182,780 (faslodex) as a male contraceptive method after 2003
History
Active ingredient is already FDA-approved and on the commercial market for the treatment of breast cancer. Pre-clinical proof-of-concept studies were conducted in the early 2000s for male contraceptive use.